Search the repository

A+ | A- | | SLO | ENG

Abstract: The main objective of the EU-funded project mitigating environmentally-assisted cracking through optimisation of surface condition (MEACTOS) was to gain knowledge on the ability of different surface machining procedures to mitigate environmentally-assisted cracking (EAC) in typical light water reactor structural materials and environments. Surfaces of cold-worked (CW) type 316L austenitic stainless steel and nickel-based weld metal Alloy 182 flat tapered tensile specimens were machined using different processes. EAC initiation susceptibility of these specimens was evaluated using constant extension rate tensile (CERT) tests under simulated boiling water reactor (BWR) and pressurized water reactor (PWR) conditions and assessed using constant load experiments. More than a hundred tests were performed covering about 10 years of autoclave testing time. Only minor or no measurable improvements in EAC initiation susceptibility as a function of surface treatments (grinding or advanced machining) compared to the standard industrial face milling were demonstrated. In most cases, the stress thresholds for EAC initiation determined in constant load tests confirmed the trend obtained from CERT tests. This paper summarises the most important results and conclusions concerning the EAC initiation behaviour for the CW 316L and Alloy 182 under reducing PWR and oxidizing BWR conditions.
Keywords: crack initiation, environmentally-assisted cracking, Alloy 182, AISI 304 stainless steel, surface treatment, light water reactor, open access
Published in DiRROS: 30.05.2023; Views: 12; Downloads: 6
Full text (16,31 MB)
This document has many files! More...

Abstract: The present retrospective study was undertaken to investigate the association of relative dose intensity (RDI) with the outcome of patients with advanced stage Hodgkin lymphoma (HL) receiving ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and escalated BEACOPP regimens (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone). A total of 114 patients with HL treated between 2004 and 2013 were enrolled for evaluation. The association of variables with overall survival (OS) and progression-free survival (PFS) was analysed using univariate and multivariate Cox proportional hazards models. The median age of patients was 39 years, and the majority were male and had stage IV disease. A total of 54 patients received ABVD and 60 received BEACOPP chemotherapy with 24 and four deaths, respectively. Patients in the BEACOPP group were significantly younger with lower Charlson comorbidity index (CCI) and better performance status in comparison with the ABVD group, making the comparison of groups not possible. In the ABVD group, RDI was not significantly associated with OS (P=0.590) or PFS (P=0.354) in a multivariate model where age was controlled. The low number of events prevented this analysis in the BEACOPP group. The age of patients was strongly associated with both OS and PFS; all statistically significant predictors for OS and PFS from univariate analyses (chemotherapy regimen, CCI, RDI, performance status) lost their effect in multivariate analyses where age was controlled. Based on these observations, it was concluded that RDI was not associated with OS or PFS after age is controlled, neither in all patients combined nor in the ABVD group.
Keywords: Hodgkin lymphoma, chemotherapy, outcome, primary treatment
Published in DiRROS: 23.09.2022; Views: 270; Downloads: 83
Full text (794,55 KB)

Abstract: Multimodal treatment approaches, such as radio-immunotherapy, necessitate regimen optimization and the investigation of the interactions of different modalities. The aim of this study was two-fold. Firstly, to select the most effective combination of irradiation and the previously developed tumor cell-based vaccine and then to provide insight into the immune response to the selected combinatorial treatment. The study was performed in immunologically different murine tumor models: B16F10 melanoma and CT26 colorectal carcinoma. The most effective combinatorial treatment was selected by comparing three different IR regimens and three different vaccination regimens. We determined the local immune response by investigating immune cell infiltration at the vaccination site and in tumors. Lastly, we determined the systemic immune response by investigating the amount of tumor-specific effector lymphocytes in draining lymph nodes. The selected most effective combinatorial treatment was 5× 5 Gy in combination with concomitant single-dose vaccination (B16F10) or with concomitant multi-dose vaccination (CT26). The combinatorial treatment successfully elicited a local immune response at the vaccination site and in tumors in both tumor models. It also resulted in the highest amount of tumor-specific effector lymphocytes in draining lymph nodes in the B16F10, but not in the CT26 tumor-bearing mice. However, the amount of tumor-specific effector lymphocytes was intrinsically higher in the CT26 than in the B16F10 tumor model. Upon the selection of the most effective combinatorial treatment, we demonstrated that the vaccine elicits an immune response and contributes to the antitumor efficacy of tumor irradiation. However, this interaction is multi-faceted and appears to be dependent on the tumor immunogenicity.
Keywords: experimental oncology, multimodal treatment, radio-imunotherapy
Published in DiRROS: 14.09.2022; Views: 234; Downloads: 104
Full text (9,70 MB)
This document has many files! More...

Abstract: Background: SARS-CoV-2 vaccination in cancer patients is crucial to prevent severe COVID-19 disease course. Methods: This study assessed immunogenicity of cancer patients on active treatment receiving mRNA-based SARS-CoV-2 vaccine by detection of anti-SARS-CoV-2 S1 IgG antibodies in serum, before, after the first and second doses and 3 months after a complete primary course of vaccination. Results were compared with healthy controls. Results: Of 112 patients, the seroconversion rate was 96%. A significant reduction in antibody levels was observed 3 months after vaccination in patients receiving immune checkpoint inhibitors versus control participants (p < 0.001). Adverse events were mostly mild. Conclusion: Immunogenicity after mRNA-based vaccine in cancer patients is adequate but influenced by the type of anticancer therapy. Antibody levels decline after 3 months, and thus a third vaccination is warranted.
Keywords: onkološko zdravljenje, imunogenost, osnovno cepljenje mRNA, čvrsti tumorji, anticancer treatment, immunogenicity, mRNA-based vaccination, solid cancer
Published in DiRROS: 24.06.2022; Views: 462; Downloads: 175
Full text (2,03 MB)

Keywords: deep cryogenic treatment, tribological properties, ferrous alloy
Published in DiRROS: 22.06.2022; Views: 243; Downloads: 70
Link to file